Survodutide

10 Vials of 5mg or 10mg Survodutide – Lab-tested, high-purity dual GLP-1/glucagon receptor agonist peptide. Supports metabolic, obesity, and liver health research with secure payment and fast, discreet shipping.

Survodutide (BI 456906) is a dual agonist of the glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R), co-invented by Boehringer Ingelheim and Zealand Pharma.  It is currently in Phase 3 clinical trials for the treatment of obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). 

The molecule is designed to simultaneously reduce appetite (via GLP-1 activation) and increase energy expenditure (via glucagon activation), leading to superior weight loss and liver fat reduction. In Phase 2 trials, it achieved up to 18.7% body weight loss over 46 weeks and demonstrated significant improvements in liver fibrosis in MASH patients.